Red Biotechnology Market By Application (Biopharmaceutical Manufacture, Pharmacogenomics, Gene Therapy, and Genetic Testing), By End-user (Biopharmaceutical Business, Research Organizations, CMOs & CROs, and Others), and By Region - Market Trends, Analysis, and Forecast till 2029

Red Biotechnology Market accounted for USD 353.1 Billion in 2019 and is estimated to be USD 584.8 Billion by 2029 and is anticipated to register a CAGR of 5.2%

Red biotechnology is one of the fields of biotechnology. Biotechnology is spreading its roots everywhere, with the advancement in the world. Red biotechnology is a field that deals with human healthcare, health preservation, and pharmaceutical. The scientists exploit living systems to develop and produce antibiotics, vaccines, therapies, and new diagnostic methods. It is the field that deals with drug discovery, pharmacogenomics, personalized medicine, gene therapy, and genetic testing. Further, red biotechnology also has its application in cancer research and biochip production.

Increasing demand for therapeutics to drive new potentials

The increasing prevalence of chronic diseases is fascinating researchers to develop advanced drugs and therapeutics that are proficient in battling chronic and progressive diseases. Further, due to continuous developments in therapeutics for an array of diseases, and perpetual efforts towards effective R&D for drug development, product approvals by international regulatory bodies are obtaining major traction, thus driving developments in the red biotechnology market.

Substantial investments in the healthcare sector

There is an incessantly rising buoyancy for supporting industries in the biotech sector, including health service firms. Healthcare start-ups are admiring intensely for investors, principally in areas such as biotechnology. The healthcare industry, as a whole, has cited that dollars of investments and higher valuations are likely to stay consistent throughout the forecast period, giving an edge to research activities for biopharmaceutical production.

However, the high cost of manufacturing and the high failure rate of late-stage drug products in clinical trials are major factors hampering the red biotechnology market growth. Significantly large funds are needed for the research and development of therapeutics, which results in the higher prices of therapeutics and leads to concerns regarding funds, thus, limiting the penetration of therapeutics in emerging economies that provides significant opportunities.

The red biotechnology market is segmented based on application, end-user, and region.

On the basis of the application, the red biotechnology market is segmented into biopharmaceutical manufacture, pharmacogenomics, gene therapy, and genetic testing. Based on the end-user, the target market is segmented into biopharmaceutical business, research organizations, CMOs & CROs, and others.

In the region, the red biotechnology market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America estimates for the highest share of the red biotechnology market in 2018. The region is projected to continue its dominance in the red biotechnology market in the coming years. A higher rate of adoption of new diagnostics and therapeutics along with the growing demand for efficient drug products is expected to fuel the red biotechnology market in North America. In Europe, the market is projected to grow at a substantial growth rate in the near future, due to rising product approvals, increasing prevalence of genetic disorders, rising mergers & acquisitions, and surging funding for research & development. Further, in the Asia Pacific, the target market is likely to grow at a substantial CAGR in the coming years. Increasing mergers & acquisitions and product approvals in the region from respective regional authorities are expected to dive into the red biotechnology market over the forecast period. For instance, in May 2019, Takeda Pharmaceutical Company declared the agreement of Entyvio by the Ministry of Health, Labour, and Welfare in Japan for the treatment of adult patients with moderately to severely active Crohn’s disease.

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029.  For the purpose of this study, has segmented the red biotechnology market report based on application, end-user, and region.

 Red Biotechnology Market, By Application:

• Drug Development
• Molecular Genomics
• Gene Therapy
• Personalized Medicines
• Others

Red Biotechnology Market, By End-user:

• Biopharmaceutical Business
• Research Organizations
• CMOs & CROs
• Others

Red Biotechnology Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the red biotechnology market include Biogen Inc., Pfizer, Inc., Amgen Inc., AstraZeneca Plc., CELGENE CORPORATION, Gilead Sciences, Inc., F. Hoffmann-La Roche, Ltd., Regeneron Pharmaceuticals, Inc., Merck KGaA, and Takeda Pharmaceutical Company Limited. Companies operating in the red biotechnology market are expanding their focus towards the expansion of geographic presence through partnerships, strategic mergers & acquisitions, and product launches in different regions and countries, thus merging their position in the red biotechnology market.

• Biogen Inc.
• Pfizer, Inc.
• Amgen, Inc.
• AstraZeneca Plc.
• CELGENE CORPORATION
• Glead Sciences, Inc.
• F. Hoffmann-La Roche, Ltd.
• Regeneron Pharmaceuticals, Inc.
• Merck KGaA
• Takeda Pharmaceutical Company Limited